- Report
- March 2024
- 199 Pages
Global
From €3244EUR$3,374USD£2,783GBP
€3605EUR$3,749USD£3,092GBP
- Report
- February 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- October 2023
- 181 Pages
Global
From €4712EUR$4,900USD£4,042GBP
- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- December 2023
- 140 Pages
Global
From €4279EUR$4,450USD£3,671GBP
- Report
- March 2018
- 220 Pages
Global
From €2115EUR$2,200USD£1,815GBP
- Report
- February 2023
- 198 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- February 2024
- 227 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- February 2024
- 114 Pages
China
From €1731EUR$1,800USD£1,485GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
Zaleplon is a sedative-hypnotic drug used to treat insomnia. It is classified as a Central Nervous System (CNS) drug, and is a member of the pyrazolopyrimidine class of drugs. Zaleplon works by binding to the GABA-A receptor, which increases the activity of the neurotransmitter GABA, resulting in sedation and relaxation. It is typically prescribed for short-term use, as it can cause dependence and tolerance if used for longer periods of time.
Zaleplon is available in both generic and brand-name formulations, and is sold in the United States, Canada, and Europe. It is typically taken orally, and is available in capsule and tablet form.
The market for Zaleplon is highly competitive, with several major pharmaceutical companies competing for market share. Some of the companies in the market include Sunovion Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more